UB Paderborn / Katalog / Suche / in CDI

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

Clinical pharmacology and therapeutics, 2011-01, Vol.89 (1), p.65-74

2011

Volltextzugriff (PDF)

Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study

Journal of thrombosis and haemostasis, 2017-11, Vol.15 (11), p.2125-2137

2017

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2011-04, Vol.13 (4), p.357-365

2011

Volltextzugriff (PDF)

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

Clinical pharmacology and therapeutics, 2011-08, Vol.90 (2), p.287-295

2011

Volltextzugriff (PDF)

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

Diabetes, obesity & metabolism, 2013-03, Vol.15 (3), p.280-283

2013

Volltextzugriff (PDF)

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2016-03, Vol.18 (3), p.236-240

2016

Volltextzugriff (PDF)

Model‐Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery

CPT: pharmacometrics and systems pharmacology, 2014-09, Vol.3 (9), p.1-9

2014

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2016-07, Vol.18 (7), p.678-684

2016

Volltextzugriff (PDF)

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

Diabetes, obesity & metabolism, 2011, Vol.13 (1), p.47-54

2011

Volltextzugriff (PDF)

P0790 : The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir

Journal of hepatology, 2015-04, Vol.62, p.S628-S628

2015

Volltextzugriff (PDF)

P0799 : The Pharmacokinetics of beclabuvir (BMS-791325) when administered in combination with daclatasvir and asunaprevir in treatment-naive patients with or without cirrhosis infected with HCV genotype 1

Journal of hepatology, 2015-04, Vol.62, p.S633-S634

2015

Volltextzugriff (PDF)

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

Diabetes, obesity & metabolism, 2011-08, Vol.13 (8), p.770-773

2011

Volltextzugriff (PDF)

Evaluation of 4β‐Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model

CPT: pharmacometrics and systems pharmacology, 2014-06, Vol.3 (6), p.1-10

2014

Volltextzugriff (PDF)

Bioequivalence of Fixed-Dose Combinations of Dapagliflozin/Metformin Relative to Single Components in Healthy Subjects

Clinical therapeutics, 2015-08, Vol.37 (8), p.e98-e99

2015

Volltextzugriff (PDF)

Bioequivalence and Food effect of heat-stressed and non-heat-stressed Dapagliflozin Tablets

Clinical therapeutics, 2015-08, Vol.37 (8), p.e105-e105

2015

Volltextzugriff (PDF)

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women

Diabetes, obesity & metabolism, 2012-12, Vol.14 (12), p.1155-1157

2012

Volltextzugriff (PDF)

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer

Journal of clinical oncology, 1996-01, Vol.14 (1), p.249-256

1996

Volltextzugriff (PDF)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical pharmacology: advances and applications, 2014-01, Vol.6 (default), p.179-187

2014

Volltextzugriff (PDF)

A Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.49S-58S

2000

Volltextzugriff (PDF)

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

Thrombosis and haemostasis, 2012-05, Vol.107 (5), p.916

2012

Volltextzugriff (PDF)

Effect of Multiple-Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin-Dependent Diabetes Mellitus Maintained with Diet and Exercise

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.76S-86S

2000

Volltextzugriff (PDF)

Simulation-based support of dose recommendations of entecavir for renally impaired subjects

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P20-P20

2005

Volltextzugriff (PDF)

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

Cancer research (Chicago, Ill.), 1994-03, Vol.54 (5), p.1220-1226

1994

Volltextzugriff (PDF)

Interchangeability of 400-mg Intravenous and Oral Gatifloxacin in Healthy Adults

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.59S-66S

2000

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule

Cancer research (Chicago, Ill.), 1994-02, Vol.54 (3), p.709-717

1994

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

Model‐Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery

Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

P0790 : The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir

P0799 : The Pharmacokinetics of beclabuvir (BMS-791325) when administered in combination with daclatasvir and asunaprevir in treatment-naive patients with or without cirrhosis infected with HCV genotype 1

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

Evaluation of 4β‐Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model

Bioequivalence of Fixed-Dose Combinations of Dapagliflozin/Metformin Relative to Single Components in Healthy Subjects

Bioequivalence and Food effect of heat-stressed and non-heat-stressed Dapagliflozin Tablets

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

A Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

Effect of Multiple-Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin-Dependent Diabetes Mellitus Maintained with Diet and Exercise

Simulation-based support of dose recommendations of entecavir for renally impaired subjects

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

Interchangeability of 400-mg Intravenous and Oral Gatifloxacin in Healthy Adults

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule

Suchergebnisse filtern